MDS | Tumor

CURE’s myelodysplastic syndrome (MDS) page is an extensive resource of cancer information featuring the latest myelodysplastic syndrome news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on MDS.

mRNA COVID-19 Vaccination Sparks Strong Antibody Response in Patients With AML and MDS

December 13th 2021, 9:00pm

Article

Most patients with acute myeloid leukemia and myelodysplastic syndrome achieved strong antibody responses to COVID-19 vaccination, according to recent study results.

There’s Always Hope After an ‘Incurable’ Cancer Diagnosis, Thanks to Devoted Researchers

November 18th 2021, 6:00pm

Article

A cancer survivor explains how the new treatments coming out for all types of cancer give her hope. “If we are diagnosed today, a cure or remission may come out next week or next month, or next year to give us additional time to live,” she writes.

Phase 2 Trial Initiated for Second Line Treatment of AML and MDS

November 18th 2021, 12:00am

Article

A phase 2 trial of aspacytarabine (BST-236) was initiated in patients with AML and MDS.

Cancer Survivors Are All on a Journey

September 30th 2021, 5:00pm

Article

A cancer survivor explains why each person experiences cancer differently – from side effects to treatments and more.

In the Mist of My Fear: Experiences With MDS

August 10th 2021, 1:30pm

Article

A patient with MDS writes about facing fears during the treatment journey.

The Basics of MDS: Diagnosis and Staging

August 4th 2021, 9:00pm

Article

How are myelodysplastic syndromes diagnosed and staged? What causes them? An expert from Moffit Cancer Center offers insight.

FDA Grants Venclexta/Onureg a Breakthrough Therapy Designation for Untreated MDS

July 22nd 2021, 12:00am

Article

The FDA will expedite the development and review of the drug combination to treat untreated intermediate- high- and very high-risk myelodysplastic syndrome.

Vidaza With Novel Drug Shows Improvement for Myelodysplastic Syndromes With Genetic Mutations and Acute Myeloid Leukemia

April 2nd 2021, 9:00pm

Article

Previously, Vidaza alone showed poor response rates for patients with TP53-mutated, myelodysplastic syndromes and acute myeloid leukemia, but adding the novel agent eprenetapopt improved response rates and overall survival in this patient population.

A Multidisciplinary Team in Treating Myelodysplastic Syndromes

December 17th 2020, 5:00am

Video

Possible Treatment Options for Myelodysplastic Syndromes

December 17th 2020, 5:00am

Video